Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT04862663Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2021
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of capivasertib in breast cancer (5 arms), sponsored by AstraZeneca. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 36 months and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04862663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862663.